US20070191283A1 - Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues - Google Patents

Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues Download PDF

Info

Publication number
US20070191283A1
US20070191283A1 US11/203,639 US20363905A US2007191283A1 US 20070191283 A1 US20070191283 A1 US 20070191283A1 US 20363905 A US20363905 A US 20363905A US 2007191283 A1 US2007191283 A1 US 2007191283A1
Authority
US
United States
Prior art keywords
alkyl
aryl
independently
hydrogen
hetaryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/203,639
Other languages
English (en)
Inventor
William Polvino
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Helsinn Therapeutics US Inc
Rejuvenon Corp
Original Assignee
Rejuvenon Corp
Sapphire Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rejuvenon Corp, Sapphire Therapeutics Inc filed Critical Rejuvenon Corp
Priority to US11/203,639 priority Critical patent/US20070191283A1/en
Publication of US20070191283A1 publication Critical patent/US20070191283A1/en
Priority to US12/313,956 priority patent/US8039456B2/en
Assigned to SAPPHIRE THERAPEUTICS (FORMERLY REJUVENON CORPORATION) reassignment SAPPHIRE THERAPEUTICS (FORMERLY REJUVENON CORPORATION) ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: POLVINO, WILLIAM J.
Assigned to HELSINN THERAPEUTICS (U.S.), INC. reassignment HELSINN THERAPEUTICS (U.S.), INC. MERGER (SEE DOCUMENT FOR DETAILS). Assignors: SAPPHIRE THERAPEUTICS, INC.
Priority to US12/631,490 priority patent/US8039457B2/en
Priority to US13/234,248 priority patent/US20120010157A1/en
Priority to US13/234,387 priority patent/US20120077745A1/en
Abandoned legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Definitions

  • Gastrointestinal motility is a coordinated neuromuscular process that transports nutrients through the digestive system.
  • C. Scarpignato “Pharmacological Stimulation of Gastrointestinal Motility: Where We Are And Where Are We Going?” Dig. Dis., 15: 112 (1997).
  • Impaired (i.e., slowed) motility of the gastrointestinal system which can be involved in gastroesophageal reflux disease, gastroparesis (e.g., diabetic and postsurgical), irritable bowel syndrome and constipation, is one of the largest health care burdens of industrialized nations.
  • S. D. Feighner et al. “Receptor for Motilin Identified in the Human Gastrointestinal System,” Science, 284: 2184-2188 (Jun. 25, 1999).
  • the present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system.
  • the method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • stimulation of gastrointestinal motility is used in a method of treating opioid induced constipation in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • the subject is using opioids for post-surgical pain management.
  • the subject is using opioids for chronic pain management. Suitable opioids included, but are not limited to, percocet, morphine, vicoden, methadone, oxycodone and fentanyl.
  • the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • stimulation of gastrointestinal motility is used in a method of treating diabetes related gastroparesis in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • stimulation of gastrointestinal motility is used in a method of treating gastroesophageal reflux disease (GERD) in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • the gastroesophageal reflux disease is nocturnal gastroesophageal reflux disease.
  • stimulation of gastrointestinal motility is used in a method of treating irritable bowel syndrome (IBS) in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • the irritable bowel syndrome is constipation-predominant irritable bowel syndrome.
  • the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome.
  • stimulation of gastrointestinal motility is used in a method of treating constipation in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • stimulation of gastrointestinal motility is used in a method of treating post-operative ileus in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is represented by Formulas I-V, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • the growth hormone secretagogue is represented by the structural Formula I: wherein:
  • R 1 is hydrogen, or C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl;
  • a and d are independently 0, 1, 2 or 3;
  • b and c are independently 0, 1, 2, 3, 4 or 5, provided that b+c is 3, 4 or 5;
  • D is R 2 —NH—(CR 3 R 4 ) e —(CH 2 ) f -M-(CHR 5 ) g —(CH 2 ) h —
  • R 2 , R 3 , R 4 and R 5 are independently hydrogen or C 1-6 alkyl optionally substituted with one or more halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 2 and R 3 or R 2 and R 4 or R 3 and R 4 can optionally form —(CH 2 ) i —U—(CH 2 ) j —, wherein i and j are independently 1 or 2 and U is —O—, —S— or a valence bond;
  • h and f are independently 0, 1, 2, or 3;
  • g and e are independently 0 or 1;
  • M is a valence bond, —CR 6 ⁇ CR 7 —, arylene, hetarylene, —O— or —S—;
  • R 6 and R 7 are independently hydrogen, or C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl;
  • G is —O—(CH 2 ) k —R 8
  • J is —O—(CH 2 ) l —R 13 , wherein:
  • R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 and R 17 independently are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy;
  • k and l are independently 0, 1 or 2;
  • E is —CONR 18 R 19 , —COOR 19 , —(CH 2 ) m —NR 18 SO 2 R 20 , —(CH 2 ) m —NR 18 —COR 20 , —(CH 2 ) m —OR 19 , —(CH 2 ) m —OCOR 20 , —CH(R 18 )R 19 , —(CH 2 ) m —NR 18 —CS—NR 19 R 21 or —(CH 2 ) m —NR 18 —CO—NR 19 R 21 ; or
  • E is —CONR 22 NR 23 R 24 , wherein R 22 is hydrogen, C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl, or aryl or hetaryl optionally substituted with one or more C 1-6 -alkyl; R 23 is C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl, or C 1-7 -acyl; and R 24 is hydrogen, C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl; or aryl or hetaryl optionally substituted with one or more C 1-6 -alkyl; or
  • R 22 and R 23 together with the nitrogen atoms to which they are attached can form a heterocyclic system optionally substituted with one or more C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 22 and R 24 together with the nitrogen atoms to which they are attached can form a heterocyclic system optionally substituted with one or more C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 23 and R 24 together with the nitrogen atom to which they are attached can form a heterocyclic system optionally substituted with one or more C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl;
  • n 0, 1, 2 or 3
  • R 18 , R 19 and R 21 independently are hydrogen or C 1-6 -alkyl optionally substituted with halogen, —N(R 25 )R 26 , wherein R 25 and R 26 are independently hydrogen or C 1-6 alkyl; hydroxyl, C 1-6 -alkoxy, C 1-6 -alkoxycarbonyl, C 1-6 -alkylcarbonyloxy or aryl; or R 19 is wherein
  • Q is —CH ⁇ or —N ⁇
  • K and L are independently —CH 2 —, —CO—, —O—, —S—, —NR 27 — or a valence bond, where R 27 is hydrogen or C 1-6 alkyl;
  • n and o are independently 0, 1, 2, 3 or 4;
  • R 20 is C 1-6 alkyl, aryl or hetaryl
  • the growth hormone secretagogue of Formula I is more specifically represented by the structural Formula II: or a pharmaceutically acceptable salt, solvate or hydrate thereof.
  • the growth hormone secretagogue is represented by the structural Formula III:
  • the compound of Formula III is fully described in U.S. Pat. No. 6,303,620 to Hansen, et al., the entire content of which is hereby incorporated by reference.
  • the chemical name of the compound of Formula III is 2-Amino-N- ⁇ (1R)-2-[3-benzyl-3-(N,N′,N′-trimethylhydrazinocarbonyl)piperidin-1-yl]-1-((1H-indol-3-yl)-2-oxoethyl ⁇ -2-methylpropionamide, and is referred to herein as RC-1291.
  • the growth hormone secretagogue is represented by the structural Formula IV: wherein
  • R 1 is hydrogen or C 1-6 -alkyl
  • R 2 is hydrogen or C 1-6 -alkyl
  • R 4 is hydrogen or C 1-6 alkyl
  • p is 0 or 1;
  • q, s, t, u are independently 0, 1, 2, 3, or 4;
  • R 9 , R 10 , R 11 , and R 12 are independently hydrogen or C 1-6 alkyl
  • o 0, 1 or 2;
  • T is —N(R 15 )(R 16 ) or hydroxyl
  • R 13 , R 15 , and R 16 are independently hydrogen or C 1-6 alkyl
  • R 14 is hydrogen, aryl or hetaryl
  • p is 0 or 1;
  • q, s, t, u are independently 0, 1, 2, 3, or 4;
  • r is 0 or 1;
  • R 9 , R 10 , R 11 , and R 12 are independently hydrogen or C 1-6 alkyl
  • o 0, 1, or 2;
  • T is —N(R 15 )(R 16 ) or hydroxyl
  • R 13 , R 15 , and R 16 are independently from each other hydrogen or C 1-6 alkyl
  • R 14 is hydrogen, aryl, or hetaryl
  • G is —O—(CH 2 )—R 17 , wherein:
  • R 17 , R 18 , R 19 , R 20 and R 21 independently are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy;
  • K is 0, 1 or 2;
  • J is —O—(CH 2 ) l —R 22 , wherein:
  • R 22 , R 23 , R 24 , R 25 and R 26 independently are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy;
  • l 0, 1 or 2;
  • a 0, 1, or 2;
  • b 0, 1, or 2;
  • c 0, 1, or 2;
  • d is 0 or 1
  • e 0, 1, 2, or 3;
  • f is 0 or 1;
  • R 5 is hydrogen or C 1-6 -alkyl optionally substituted with one or more hydroxyl, aryl or hetaryl;
  • R 6 and R 7 are independently hydrogen or C 1-6 -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;
  • R 8 is hydrogen or C 1-6 -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;
  • R 6 and R 7 or R 6 and R 8 or R 7 and R 8 can optionally form —(CH 2 ) i —U—(CH 2 ) j —, wherein i and j independently are 1, 2 or 3 and U is —O—, —S—, or a valence bond;
  • M is arylene, hetarylene, —O—, —S— or —CR 27 ⁇ CR 28 —,
  • R 27 and R 28 are independently hydrogen or C 1-6 -alkyl, optionally substituted with one or more aryl or hetaryl;
  • the growth hormone secretagogue of Formula IV is more specifically represented by the structural Formula V: or a pharmaceutically acceptable salt, solvate or hydrate thereof.
  • the chemical name of the compound of Formula V is (2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1- ⁇ N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl ⁇ -2-(biphenyl-4-yl)ethyl)-N-methylamide, referred to herein as RC-1139.
  • FIG. 1 is a bar graph of percentage of gastric emptying for normal rats administered saline or RC-1139 at a dose of 0.25 mg/kg, 1.0 mg/kg or 2.5 mg/kg. The results demonstrate a statistically significant decrease in gastric residue at 1.0 mg/kg and 2.5 mg/kg of RC-1139 showing a dose-related acceleration of gastric emptying.
  • FIG. 2 is a bar graph of percentage of gastric emptying for rats with induced post-operative gastric ileus administered saline or RC-1139 at a dose of 1.0 mg/kg, 2.5 mg/kg or 10 mg/kg. The results demonstrate a statistically significant decrease in gastric residue at the 2.5 mg/kg dose and the 10 mg/kg dose.
  • FIG. 3 is a bar graph of percentage of gastric emptying for rats with induced post-operative gastric ileus and morphine treatment (4 mg/kg), administered saline or RC-1139 at a dose of 2.5 mg/kg, 10 mg/kg or 50 mg/kg. The results demonstrate a statistically significant decrease in gastric residue at the 10 mg/kg dose of RC-1139.
  • FIG. 4 is a bar graph of percentage of gastric emptying for rats with induced post-operative gastric ileus and morphine treatment (12 mg/kg), administered saline or RC-1139 at a dose of 10 mg/kg. The results show that at a 10 mg/kg dose, RC-1139 did not accelerate the delayed gastric emptying over the saline treated controls.
  • FIG. 5 is a bar graph of percentage of gastric emptying for normal rats with morphine treatment (4 mg/kg) administered saline or RC-1139 at a dose of 2.5 mg/kg or 10 mg/kg. The results demonstrate a statistically significant decrease in gastric residue at the 2.5 mg/kg dose and the 10 mg/kg dose of RC-1139.
  • FIG. 6 is a bar graph of percentage of gastric emptying for normal rats with morphine treatment (12 mg/kg) administered saline or RC-1139 at a dose of 2.5 mg/kg or 10 mg/kg. The results show a decrease (non-statistically significant) in gastric residue at the 2.5 mg/kg dose and the 10 mg/kg dose of RC-1139.
  • FIG. 7 is a bar graph of estimated effective doses of RC-1139 to stimulate gastric emptying in rats subjected to the experimental conditions described herein.
  • the present invention relates to a method of stimulating the motility of the gastrointestinal system in a subject in need thereof, wherein the subject suffers from maladies (i.e., disorders or diseases) of the gastrointestinal system.
  • the method comprises administering to a subject in need thereof a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • the growth hormone secretagogue is a compound represented by any of Formulas I-XVI, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • stimulation of gastrointestinal motility is used in a method of treating opioid induced constipation in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • the subject is using opioids for post-surgical pain management.
  • the subject is using opioids for chronic pain management. Suitable opioids include, but are not limited to, percocet, morphine, vicoden, methadone, oxycodone, and fentanyl.
  • the growth hormone secretagogue is a compound represented by any of Formulas I-XVI, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • stimulation of gastrointestinal motility is used in a method of treating diabetes related gastroparesis in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is a compound represented by any of Formulas I-XVI, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • stimulation of gastrointestinal motility is used in a method of treating gastroesophageal reflux disease (GERD) in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is a compound represented by any of Formulas I-XVI, or a pharmaceutically acceptable salt, hydrate or solvate thereof is administered.
  • the gastroesophageal reflux disease is nocturnal gastroesophageal reflux disease.
  • stimulation of gastrointestinal motility is used in a method of treating irritable bowel syndrome (IBS) in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is a compound represented by any of Formulas I-XVI, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • the irritable bowel syndrome is constipation-predominant irritable bowel syndrome.
  • the irritable bowel syndrome is alternating constipation/diarrhea irritable bowel syndrome.
  • stimulation of gastrointestinal motility is used in a method of treating constipation in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is a compound represented by any of Formulas I-XVI, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • stimulation of gastrointestinal motility is used in a method of treating post-operative ileus in a subject in need thereof comprising administering a therapeutically effective amount of a growth hormone secretagogue compound.
  • the growth hormone secretagogue is represented by a compound represented by any of Formulas I-XVI, or a pharmaceutically acceptable salt, hydrate or solvate thereof.
  • opioid analgesics to relieve chronic pain can cause effects on organs outside the targets in the central nervous system.
  • the opioid action can slow stomach emptying and inhibit bowel movement.
  • the increased time of fecal contents in the intestines results in excessive absorption of water and sodium from fecal contents, resulting in harder, drier stools and constipation, afflicting approximately 90% of individuals on analgesic pain killers.
  • the resulting constipation can be a dose limiting side-effect.
  • analgesics used for post-surgical pain management can cause opioid induced constipation.
  • Suitable opioids include, but are not limited to, percocet, morphine, vicoden, methadone, oxycodone and fentanyl, or any combination thereof.
  • the method of treating opioid induced constipation comprises co-administering a growth hormone secretagogue compound with a therapeutically effective amount of a peripherally acting opioid antagonist, a laxative, or any combination thereof.
  • a peripherally acting opioid antagonist include, but are not limited to, methylnaltrexone, naltrexone, nalmefene, naloxone and alvimopan or any combination thereof.
  • Suitable laxatives include, but are not limited to bulk forming laxatives, lubricant laxatives, stool softeners, or any combination thereof.
  • Constipation is a condition in which a person has uncomfortable or infrequent bowel movements. A person with constipation produces hard stools that can be difficult to pass. The person also can feel as though the rectum has not been completely emptied. Acute constipation begins suddenly and noticeably. Chronic constipation, on the other hand, can begin insidiously and persist for months or years.
  • constipation is assessed, for example, using a rat cathartic colon model in which constipation is induced by feeding rats a contact laxative such as phenolphthalein or rhubarb (see, e.g., Liu et al., World J. Gastroenterol. 10:1672-1674 (2004)).
  • a contact laxative such as phenolphthalein or rhubarb
  • constipation is estimated as the number or weight of fecal pellets per unit time (e.g., Nakamura et al., J. Nutr. Sci. Vitaminol.
  • Rats with cathartic colon show decreased fecal output or increased gastrointestinal transit time compared to control rats.
  • the administration of a growth hormone secretagogue compound which is effective at treating constipation increases the number or weight of fecal pellets or decreases gastrointestinal transit time in the rat cathartic colon model.
  • An effective dose of growth hormone secretagogue for treating constipation can be in the range of 0.1 to 100 mg/kg, preferably in the range of 1 to 20 mg/kg, and more preferably in the range of 2 to 10 mg/kg.
  • the method of treating constipation comprises co-administering a growth hormone secretagogue compound with a therapeutically effective amount of a laxative.
  • Suitable laxatives include, but are not limited to, bulk forming laxatives, lubricant laxatives, stool softeners, or any combination thereof.
  • postoperative ileus a term denoting disruption of the normal coordinated movements of the gut, resulting in failure of the propulsion of intestinal contents. Ileus has also been defined as a functional, nonmechanical obstruction of the bowel. The term “post-operative” ileus refers to delay in normal gastric and colonic emptying.
  • the method of treating post-operative ileus comprises co-administering a growth hormone secretagogue compound with a therapeutically effective amount of a dopamine antagonist.
  • Suitable dopamine antagonists include, but are not limited to, bethanecol, metoclopramide, domperidone, amisulpride, clebopride, mosapramine, nemonapride, remoxipride, risperidone, sulpiride, sultopride and ziprasidone, or any combination thereof.
  • IBS Irritable bowel syndrome
  • IBS insulin-semiconductor styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene, bowel fibroblasts, or bronchitanib, styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-styrene-sulfene-styrene-sulfene-styl-sulfene-sulfene-
  • the effectiveness of a candidate growth hormone secretagogue compound in treating IBS can be assessed, for example, using a rat model in which colitis is induced in rats by intracolonic installation of 4% acetic acid (see, e.g., La et al., World J. Gastroenterol. 9:2791-2795 (2003)). After the colitis has subsided (e.g., about seven days after acetic acid treatment), the rats are subjected to a restraint stress test, and stress-induced fecal output is measured. Rats that have undergone colitis induction show increased stress-induced fecal output compared to control rats.
  • the administration of a growth hormone secretagogue compound which is effective at treating IBS reduces the amount of stress-induced defecation in the rat colitis model.
  • An effective dose of growth hormone secretagogue for treating IBS can be in the range of 0.1 to 100 mg/kg, preferably in the range of 1 to 20 mg/kg, and more preferably in the range of 2 to 10 mg/kg.
  • the method of treating IBS comprises co-administering a growth hormone secretagogue compound with a therapeutically effective amount of H 2 receptor antagonist; a serotonin 5-HT 4 agonist; a laxative; or any combination thereof.
  • Suitable H 2 receptor antagonists include, but are not limited to, nizatidine, ranitidine, famotidine, and cimetidine, rabeprazole, or any combination thereof.
  • Suitable 5-HT 4 receptor agonist include, but are not limited to, sumatriptan, rauwolscine, yohimbine, metoclopramide, tegaserod, or any combination thereof.
  • Suitable laxatives include, but are not limited to, bulk forming laxatives, lubricant laxatives, stool softeners, or any combination thereof.
  • Gastroesophageal reflux disease is a condition in which gastric stomach contents (e.g., bile salts) back up into the food pipe (esophagus), causing chronic regurgitation of gastric contents from the stomach into the lower esophagus. Commonly known as heartburn, GERD causes esophageal irritation and inflammation.
  • the esophageal sphincter (a ring-shaped muscle located at the lower end of the esophagus to prevent stomach contents from going backwards into the esophagus) can fail to carry out its protective duties. Instead of opening only when a person is eating or swallowing, it relaxes and allows digestive juices to reflux into the esophagus and irritate the esophageal lining.
  • the effectiveness of a candidate growth hormone secretagogue compound in treating GERD can be assessed, for example, using a rat model in which GERD is induced in rats by a pyloric ligation surgical procedure (see, e.g., Tugay et al., J. Surg. Res. 115:272-8 (2003)) in conjunction with the rat gastric emptying assay described below (see “Study in a Rat Model” under “Normal Conscious Rats”).
  • the gastric emptying assay can be performed after the rats have recovered from surgery. Sham operated rats can be used as controls. Rats that have undergone pyloric ligation have higher amounts of gastric radioactivity at the end of the assay compared with control rats.
  • a growth hormone secretagogue compound which is effective at treating GERD reduces the amount of gastric radioactivity at the end of the assay.
  • An effective dose of growth hormone secretagogue for treating GERD can be in the range of 0.1 to 100 mg/kg, preferably in the range of 1 to 20 mg/kg, and more preferably in the range of 2 to 10 mg/kg.
  • the method of treating GERD comprises co-administering a growth hormone secretagogue compound with a therapeutically effective amount of H 2 receptor antagonist; an antacid; a proton pump inhibitor; or any combination thereof.
  • the effectiveness of a candidate growth hormone secretagogue compound in treating gastroparesis can be assessed, for example, using the rat gastric emptying assay described below (see “Study in a Rat Model” under “Normal Conscious Rats”). Rats with diabetes induced using streptozotocin are compared to controls. See, e.g., Rees et al., Diabet. Med. 22:359-70 (2005) for a discussion of various rat models of diabetes. Rats showing diabetes-induced gastroparesis have higher amounts of gastric radioactivity at the end of the assay compared with normal control rats.
  • a growth hormone secretagogue compound which is effective at treating diabetes-induced gastroparesis reduces the amount of gastric radioactivity at the end of the assay.
  • An effective dose of growth hormone secretagogue for treating diabetes-induced gastroparesis can be in the range of 0.1 to 100 mg/kg, preferably in the range of 1 to 20 mg/kg, and more preferably in the range of 2 to 10 mg/kg.
  • the diabetic rat gastric motility assay can be used to determine an optimum effective dose for a given candidate compound.
  • Suitable H 2 receptor antagonist include, but are not limited to, nizatidine, ranitidine, famotidine, and cimetidine, rabeprazole, or any combination thereof.
  • Suitable antacids include, but are not limited to, aluminum and magnesium hydroxide and combinations thereof.
  • Suitable proton pump inhibitors include, but are not limited to, esomeprazole (NEXIUM®), omeprazole, lansoprazole, pantoprazole, or a combination thereof.
  • Gastroparesis also referred to as delayed gastric emptying, is a disorder in which the stomach takes too long to empty its contents. It often occurs in people with type 1 diabetes or type 2 diabetes. Gastroparesis can occur when nerves to the stomach are damaged or stop working. The vagus nerve controls the movement of food through the digestive tract. If the vagus nerve is damaged, the muscles of the stomach and intestines do not work normally, and the movement of food is slowed or stopped. Diabetes can damage the vagus nerve if blood glucose levels remain high over a long period of time. High blood glucose causes chemical changes in nerves and damages the blood vessels that carry oxygen and nutrients to the nerves.
  • the effectiveness of a candidate growth hormone secretagogue compound in treating gastroparesis can be assessed, for example, using the rat gastric emptying assay described below (see “Study in a Rat Model” under “Normal Conscious Rats”). Rats with diabetes induced using streptozotocin are compared to controls. See, e.g., Rees et al., Diabet. Med. 22:359-70 (2005) for a discussion of various rat models of diabetes. Rats showing diabetes-induced gastroparesis have higher amounts of gastric radioactivity at the end of the assay compared with normal control rats.
  • a growth hormone secretagogue compound which is effective at treating diabetes-induced gastroparesis reduces the amount of gastric radioactivity at the end of the assay.
  • An effective dose of growth hormone secretagogue for treating diabetes-induced gastroparesis can be in the range of 0.1 to 100 mg/kg, preferably in the range of 1 to 20 mg/kg, and more preferably in the range of 2 to 10 mg/kg.
  • the method of treating diabetes related gastroparesis comprises co-administering a growth hormone secretagogue compound with a therapeutically effective amount of dopamine antagonist.
  • dopamine antagonists include, but are not limited to, bethanecol, metoclopramide, domperidone, amisulpride, clebopride, mosapramine, nemonapride, remoxipride, risperidone, sulpiride, sultopride and ziprasidone, or any combination thereof.
  • the invention further relates to pharmaceutical compositions useful for stimulating (i.e., inducing) motility of the gastrointestinal system.
  • the pharmaceutical composition comprises a growth hormone secretagogue and optionally a pharmaceutically acceptable carrier.
  • the pharmaceutical composition can comprise a second amount of a suitable therapeutic agent.
  • a suitable therapeutic agent can be determined based on the condition being treated in the subject.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of a laxative when treating constipation.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and laxative can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of a H 2 receptor antagonist.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and H 2 receptor antagonist can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of a serotonin 5-HT 4 agonist.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and serotonin 5-HT 4 agonist can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of an antacid.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and antacid can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of an opioid antagonist.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and opioid antagonist can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of a proton pump inhibitor.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and proton pump inhibitor can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of a motilin receptor agonist.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and motilin receptor agonist can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of a dopamine antagonist.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and dopamine antagonist can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of a cholinesterase inhibitor.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and cholinesterase inhibitor can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of somatostatin.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and somatostatin can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the pharmaceutical composition can comprise a first amount of a growth hormone secretagogue and a second amount of octreotide.
  • the pharmaceutical composition of the present invention can optionally contain a pharmaceutically acceptable carrier.
  • the growth hormone secretagogue and octreotide can each be present in the pharmaceutical composition in a therapeutically effective amount.
  • said first and second amount can together comprise a therapeutically effective amount.
  • the invention further relates to use of a growth hormone secretagogue compound for the manufacture of a medicament for stimulating (i.e., inducing) the motility of the gastrointestinal system.
  • growth hormone secretagogue compound and ghrelin agonist are synonymous.
  • a growth hormone secretagogue or ghrelin agonist therefore refers to a substance (e.g., a molecule, a compound) which promotes (induces or enhances) at least one function characteristic of a growth hormone secretagogue receptor (GHS receptor) also referred to in the art as a ghrelin receptor.
  • GHS receptor growth hormone secretagogue receptor
  • the growth hormone secretagogue compound or ghrelin agonist binds the GHS receptor or ghrelin receptor (i.e., is a ghrelin or GHS receptor agonist) and induces the secretion of growth hormone.
  • a compound having GHS receptor agonist activity can be identified and activity assessed by any suitable method.
  • the binding affinity of a GHS receptor agonist to the GHS receptor can be determined employing receptor binding assays and growth hormone stimulation can be assessed as described in Published International Application No. WO 00/01726, incorporated herein by reference.
  • GHS receptors and ghrelin receptors are expressed in the hypothalamus, pituitary and pancreas, among other tissues. Activation of these receptors in the pituitary induces the secretion of growth hormone. In addition to inducing the secretion of growth hormone, recent studies have shown the growth hormone secretagogues can increase appetite and body weight. At typical doses, growth hormone secretagogues are also known to induce the secretion of IGF-1. In a particular embodiment, the growth hormone secretagogue compounds are those described in U.S. Pat. Nos. 6,303,620, 6,576,648, 5,977,178, 6,566,337, 6,083,908, 6,274,584 and Published International Application No. WO 00/01726, the entire content of all of which are incorporated herein by reference.
  • the growth hormone secretagogue is represented by the structural Formula I: wherein:
  • R 1 is hydrogen, or C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl;
  • a and d are independently 0, 1, 2 or 3;
  • b and c are independently 0, 1, 2, 3, 4 or 5, provided that b+c is 3, 4 or 5;
  • D is R 2 —NH—(CR 3 R 4 ) e —(CH 2 ) f -M-(CHR 5 ) g —(CH 2 ) h —
  • R 2 , R 3 , R 4 and R 5 are independently hydrogen or C 1-6 alkyl optionally substituted with one or more halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 2 and R 3 or R 2 and R 4 or R 3 and R 4 can optionally form —(CH 2 ) i —U—(CH 2 ) j —, wherein i and j are independently 1 or 2 and U is —O—, —S— or a valence bond;
  • h and f are independently 0, 1, 2, or 3;
  • g and e are independently 0 or 1;
  • M is a valence bond, —CR 6 ⁇ CR 7 —, arylene, hetarylene, —O— or —S—;
  • R 6 and R 7 are independently hydrogen, or C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl;
  • G is —O—(CH 2 ) k —R 8
  • J is —(CH 2 ) l —R 13 , wherein:
  • R 8 , R 9 , R 10 , R 11 , R 12 , R 13 , R 14 , R 15 , R 16 and R 17 independently are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy;
  • k and l are independently 0, 1 or 2;
  • E is —CONR 18 R 19 , —COOR 19 , —(CH 2 ) m —NR 18 SO 2 R 20 , —(CH 2 ) m —NR 18 —COR 20 , —(CH 2 ) m —OR 19 , —(CH 2 ) m —OCOR 20 , —CH(R 18 )R 19 , —(CH 2 ) m —NR 18 —CS—NR 19 R 21 or —(CH 2 ) m —NR 18 —CO—NR 19 R 21 ; or
  • E is —CONR 22 NR 23 R 24 , wherein R 22 is hydrogen, C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl, or aryl or hetaryl optionally substituted with one or more C 1-6 -alkyl; R 23 is C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl, or C 1-7 -acyl; and R 24 is hydrogen, C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl; or aryl or hetaryl optionally substituted with one or more C 1-6 -alkyl; or
  • R 22 and R 23 together with the nitrogen atoms to which they are attached can form a heterocyclic system optionally substituted with one or more C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 22 and R 24 together with the nitrogen atoms to which they are attached can form a heterocyclic system optionally substituted with one or more C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 23 and R 24 together with the nitrogen atom to which they are attached can form a heterocyclic system optionally substituted with one or more C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl;
  • n 0, 1, 2 or 3
  • R 18 , R 19 and R 21 independently are hydrogen or C 1-6 -alkyl optionally substituted with halogen, —N(R 25 )R 26 , wherein R 25 and R 26 are independently hydrogen or C 1-6 alkyl; hydroxyl, C 1-6 -alkoxy, C 1-6 -alkoxycarbonyl, C 1-6 -alkylcarbonyloxy or aryl; or R 19 is wherein
  • Q is —CH ⁇ or —N ⁇
  • K and L are independently —CH 2 —, —CO—, —O—, —S—, —NR 27 — or a valence bond, where R 27 is hydrogen or C 1-6 alkyl;
  • n and o are independently 0, 1, 2, 3 or 4;
  • R 20 is C 1-6 alkyl, aryl or hetaryl
  • R 1 is C 1-6 -alkyl. In yet another embodiment, a is 1.
  • d is 1. In another embodiment, b+c is 4.
  • D is N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-(2-aminoethyl)-2-aminoethyl-N-phenyl
  • R 2 , R 3 , R 4 and R 5 are independently hydrogen or C 1-6 alkyl optionally substituted with a halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 2 and R 3 or R 2 and R 4 or R 3 and R 4 can optionally form —(CH 2 ) i —U—(CH 2 ) j —, wherein i and j are independently 1 or 2 and U is —O—, —S— or a valence bond;
  • h and f are independently 0, 1, 2, or 3;
  • g and e are independently 0 or 1;
  • M is —CR 6 ⁇ CR 7 —, arylene, hetarylene, —O— or —S—;
  • R 6 and R 7 are independently hydrogen, or C 1-6 -alkyl.
  • D is
  • R 2 , R 3 , R 4 and R 5 are independently hydrogen or C 1-6 alkyl optionally substituted with a halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 2 and R 3 or R 2 and R 4 or R 3 and R 4 can optionally form —(CH 2 ) i —U—(CH 2 ) j —, wherein i and j are independently 1 or 2 and U is —O—, —S— or a valence bond; h and f are independently 0, 1, 2, or 3; g and e are independently 0 or 1; M is a valence bond.
  • G is wherein:
  • R 8 , R 9 , R 10 , R 11 and R 12 independently are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 alkoxy; and k is 0, or 2.
  • J is wherein:
  • R 13 , R 14 , R 15 R 16 and R 17 independently are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy.
  • E is —CONR 18 R 19 , —COOR 19 or —(CH 2 ) m —OR 19 , wherein:
  • n 0, 1, 2 or 3;
  • R 18 and R 19 independently are hydrogen or C 1-6 -alkyl optionally substituted by halogen, —N(R 25 )R 26 wherein R 25 and R 26 are independently hydrogen or C 1-6 alkyl; hydroxyl, C 1-6 -alkoxy, C 1-6 -alkoxycarbonyl, C 1-6 -alkylcarbonyloxy or aryl.
  • E is —CONR 22 NR 23 R 24
  • R 22 is hydrogen, C 1-6 -alkyl optionally substituted with an aryl or hetaryl, or aryl or hetaryl optionally substituted with a C 1-6 -alkyl;
  • R 23 is C 1-6 -alkyl optionally substituted with one or more aryl or hetaryl, or C 1-7 -acyl;
  • R 24 is hydrogen, C 1-6 -alkyl optionally substituted with an aryl or hetaryl; or aryl or hetaryl optionally substituted with a C 1-6 -alkyl; or
  • R 22 and R 23 together with the nitrogen atoms to which they are attached can form a heterocyclic system optionally substituted with a C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl; or R 22 and R 24 together with the nitrogen atoms to which they are attached can form a heterocyclic system optionally substituted with a C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl; or
  • R 23 and R 24 together with the nitrogen atom to which they are attached can form a heterocyclic system optionally substituted with a C 1-6 -alkyl, halogen, amino, hydroxyl, aryl or hetaryl.
  • the growth hormone secretagogue is represented by the structural Formula II:
  • the compound of Formula II has the (R) configuration at the chiral carbon designated by the asterisk (*) in Formula II.
  • the chemical name of the compound of Formula II having the (R) configuration at the designated chiral carbon is: 2-Amino-N- ⁇ (1R)-2-[3-benzyl-3-(N,N′,N′-trimethylhydrazinocarbonyl)piperidin-1-yl]-1-((1H-indol-3-yl)-2-oxoethyl ⁇ -2-methylpropionamide.
  • structural Formula III Represented by structural Formula III:
  • the growth hormone secretagogue is represented by the structural Formula IV: wherein
  • R 1 is hydrogen or C 1-6 -alkyl
  • R 2 is hydrogen or C 1-6 -alkyl
  • R 4 is hydrogen or C 1-6 alkyl
  • p is 0 or 1;
  • q, s, t, u are independently 0, 1, 2, 3, or 4;
  • R 9 , R 10 , R 11 , and R 12 are independently hydrogen or C 1-6 alkyl
  • o 0, 1 or 2;
  • T is —N(R 15 )(R 16 ) or hydroxyl
  • R 13 , R 15 , and R 16 are independently hydrogen or C 1-6 alkyl
  • R 14 is hydrogen, aryl or hetaryl
  • p is 0 or 1;
  • q, s, t, u are independently 0, 1, 2, 3, or 4;
  • r is 0 or 1;
  • R 9 , R 10 , R 11 , and R 12 are independently hydrogen or C 1-6 alkyl
  • o 0, 1, or 2;
  • T is —N(R 15 )(R 16 ) or hydroxyl
  • R 13 , R 15 , and R 16 are independently from each other hydrogen or C 1-6 alkyl
  • R 14 is hydrogen, aryl, or hetaryl
  • G is —O—(CH 2 )—R 17 , wherein:
  • R 17 , R 18 , R 19 , R 20 and R 21 independently are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy;
  • K is 0, 1 or 2;
  • J is —O—(CH 2 ) l —R 22 , wherein:
  • R 22 , R 23 , R 24 , R 25 and R 26 independently are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy;
  • l 0, 1 or 2;
  • a 0, 1, or 2;
  • b 0, 1, or 2;
  • c 0, 1, or 2;
  • d is 0 or 1
  • e 0, 1, 2, or 3;
  • f is 0 or 1;
  • R 5 is hydrogen or C 1-6 -alkyl optionally substituted with one or more hydroxyl, aryl or hetaryl;
  • R 6 and R 7 are independently hydrogen or C 1-6 -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;
  • R 8 is hydrogen or C 1-6 -alkyl, optionally substituted with one or more halogen, amino, hydroxyl, aryl, or hetaryl;
  • R 6 and R 7 or R 6 and R 8 or R 7 and R 8 can optionally form —(CH 2 ) i —U—(CH 2 ) j —, wherein i and j independently are 1, 2 or 3 and U is —O—, —S—, or a valence bond;
  • M is arylene, hetarylene, —O—, —S— or —CR 27 ⁇ CR 28 —;
  • R 27 and R 28 are independently hydrogen or C 1-6 -alkyl, optionally substituted with one or more aryl or hetaryl;
  • R 1 is C 1-6 -alkyl.
  • R 2 is C 1-6 -alkyl.
  • L is wherein R 4 is hydrogen or C 1-6 alkyl; p is 0 or 1; q, s, t, u are independently from each other 0, 1, 2, 3 or 4; r is 0 or 1; the sum q+r+s+t+u is 0, 1, 2, 3, or 4; R 9 , R 10 , R 11 , and R 12 are independently from each other hydrogen or C 1-6 alkyl; Q is >N—R 13 or wherein:
  • o 0, 1 or 2;
  • T is —N(R 15 )(R 16 ) or hydroxyl
  • R 13 , R 15 , and R 16 are independently from each other hydrogen or C 1-6 alkyl
  • R 14 is hydrogen, aryl or hetaryl.
  • L is wherein:
  • q, s, t, u are independently from each other 0, 1, 2, 3 or 4;
  • r is 0 or 1;
  • R 9 , R 10 , R 11 , and R 12 are independently from each other hydrogen or C 1-6 alkyl
  • o 0, 1 or 2;
  • T is —N(R 15 )(R 16 ) or hydroxyl
  • R 13 , R 15 , and R 16 are independently from each other hydrogen or C 1-6 alkyl
  • R 14 is hydrogen, aryl or hetaryl.
  • G is wherein:
  • R 17 , R 18 , R 19 , R 20 and R 21 independently from each other are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy.
  • J is wherein:
  • R 22 , R 23 , R 24 , R 25 and R 26 independently from each other are hydrogen, halogen, aryl, hetaryl, C 1-6 -alkyl or C 1-6 -alkoxy.
  • M is arylene or —CR 27 ⁇ CR 28 —, wherein R 27 and R 28 independently from each other hydrogen or C 1-6 -alkyl, optionally substituted with aryl or hetaryl.
  • R 6 and R 7 independently from each other are hydrogen or C 1-6 -alkyl.
  • R 6 and R 7 form —(CH 2 ) i —U—(CH 2 ) j —, wherein i and j independently from each other are 1, 2 or 3 and U is —O—, —S—, or a valence bond.
  • R 8 is hydrogen or C 1-6 -alkyl.
  • the growth hormone secretagogue compound is represented by the structural Formula V.
  • the chemical name of the compound of Formula V is (2E)-5-Amino-5-methylhex-2-enoic acid N-((1R)-1- ⁇ N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbamoyl ⁇ -2-(biphenyl-4-yl)ethyl)-N-methylamide, also referred to herein as RC-1139.
  • the RC-1139 is represented by structural Formula V: and pharmaceutically acceptable salts thereof.
  • the growth hormone secretagogue is represented by structural Formula VI or a pharmaceutically acceptable salt, solvate or hydrate thereof.
  • the chemical name for the compound represented by structural Formula VI is: (2E)-4-(1-aminocyclobutyl)but-2-enoic acid N-((1R)-1- ⁇ N-[(1R)-1-benzyl-2-(4-hydroxypiperidin-1-yl)-2-oxoethyl]-N-methylcarbomoyl ⁇ -2-(biphenyl-4-yl)ethyl)-N-methylamide.
  • the growth hormone secretagogue is represented by structural Formula VII or a pharmaceutically acceptable salt, solvate or hydrate thereof.
  • the chemical name of the compound represented by structural Formula VII is: (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1- ⁇ N-methyl-N-[(1R)-2-phenyl-1-(N,N′,N′-trimethylhydrazinocarbonyl)ethyl]carbamoyl ⁇ -2-(2-naphthyl)ethyl)amide.
  • the growth hormone secretagogue is represented by structural Formula VIII or a pharmaceutically acceptable salt, solvate or hydrate thereof.
  • the chemical name of the compound represented by structural Formula VIII is: (2E)-5-amino-5-methylhex-2-enoic acid N-methyl-N-((1R)-1- ⁇ N-methyl-N-[(1R)-2-phenyl-1-(N,N′,N′-trimethylhydrazinocarbonyl)ethyl]carbamoyl ⁇ 2-(2-naphthyl)ethyl)amide.
  • the growth hormone secretagogue is represented by structural Formula IX or a pharmaceutically acceptable salt, solvate or hydrate thereof.
  • the chemical name for the compound represented by structural Formula IX is: 2-amino-N-(2-(2-(N-((2R)-2-(N-((2E)-5-amino-5-methylhex-2-enoyl)-N-methylamino)-3-(2-napthyl)propionyl)-N-methylamino)ethyl)phenyl)acetamide.
  • the growth hormone secretagogue can be selected from GHRP-1 (Formula X), GHRP-2 (Formula XI), GHRP-6 (Formula XII), NN703 (Formula XIII), Ipamorelin (Formula XIV), Capromorelin (Formula XV) and MK-677 (Formula XVI) and analogs of any of the above.
  • Peripherally acting opioid receptor antagonists such as methylnaltrexone, naloxone, naltrexone, nalmefene and alvimopan (ENTEREGTM), which do not cross the blood-brain barrier, can be administered to treat opioid induced side effects without provoking opioid withdrawal symptoms or reverse analgesia.
  • opioid receptor antagonists such as methylnaltrexone, naloxone, naltrexone, nalmefene and alvimopan (ENTEREGTM)
  • ENTEREGTM methylnaltrexone, naloxone, naltrexone, nalmefene and alvimopan
  • peripherally acting opioid antagonists refer to opioid antagonists that act peripherally (i.e., not centrally, for example, do not act on the central nervous system).
  • Proton pump inhibitors suppress gastric acid secretion, the final step of acid production, by specific inhibition of the H + K + -ATPase enzyme system at the secretory surface of gastric parietal cells.
  • Proton pump inhibitors include benzimidazole compounds, for example, esomeprazole (NEXIUM®), omeprazole (PRILOSECTM), lansoprazole (PREVACIDTM), and pantoprazole. These proton pump inhibitors contain a sulfinyl group situated between substituted benzimidazole and pyridine rings.
  • esomeprazole, omeprazole, lansoprazole, and pantoprazole are chemically stable, lipid soluble, weak bases that are devoid of inhibitory activity. These uncharged weak bases reach parietal cells from the blood and diffuse into the secretory canaliculi, where the drugs become protonated and thereby trapped.
  • the protonated species rearranges to form a sulfenic acid and a sulfenamide, the latter species capable of interacting with sulfhydryl groups of H + K + -ATPase. Full inhibition occurs with two molecules of inhibitor per molecule of enzyme.
  • the specificity of the effects of proton pump inhibitors is believed to derive from: a) the selective distribution of H + K + -ATPase; b) the requirement for acidic conditions to catalyze generation of the reactive inhibitor; and c) the trapping of the protonated drug and the cationic sulfenamide within the acidic canaliculi and adjacent to the target enzyme.
  • Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, pp. 901-915 (1996), incorporated herein by reference.
  • H 2 receptor antagonists competitively inhibit the interaction of histamine with H 2 receptors. They are highly selective and have little or no effect on H 1 receptors. Although H 2 receptors are present in numerous tissues, including vascular and bronchial smooth muscle, H 2 receptor antagonists interfere remarkably little with physiological functions other than gastric acid secretion. H 2 receptor antagonists include, but are not limited to, nizatidine (AXIDTM), ranitidine (ZANTACTM and TRITECTM), famotidine (PEPCID ACTM), and cimetidine (TAGAMETTM) and rabeprazole (ACIPHEXTM). Goodman & Gilman's The Pharmacological Basis of Therapeutics, 9th Edition, pp. 901-915 (1996), incorporated herein by reference.
  • H 2 receptor antagonists inhibit gastric acid secretion elicited by histamine, other H 2 agonists, gastrin, and, to a lesser extent, muscarinic agonists. H 2 receptor antagonists also inhibit basal and nocturnal acid secretion.
  • Compounds of the invention can be administered with antacids to neutralize gastric acid.
  • antacids for example, aluminum and magnesium hydroxide (MAALOXTM and MYLANTATM) neutralize gastric acidity, resulting in increase in pH in the stomach and duodenal bulb.
  • MAALOXTM and MYLANTATM aluminum and magnesium hydroxide
  • Laxatives come in various forms: liquids, tablets, suppositories, powders, granules, capsules, chewing gum, chocolate-flavored wafers, and caramels.
  • the basic types of laxatives are bulk-forming laxatives, lubricant laxatives, stool softeners (also called emollient laxatives), and stimulant laxatives.
  • Bulk-forming laxatives contain materials, such as cellulose and psyllium, that pass through the digestive tract without being digested. In the intestines, these materials absorb liquid and swell, making the stool soft, bulky, and easier to pass. The bulky stool then stimulates the bowel to move.
  • Laxatives in this group include such brands as FIBERCON®, FIBERALL®, and METAMUCIL®.
  • Mineral oil is the mostly widely used lubricant laxative. Taken by mouth, the oil coats the stool. This keeps the stool moist and soft and makes it easier to pass. Lubricant laxatives are often used for patients who need to avoid straining (e.g., after abdominal surgery).
  • stool softeners make stools softer and easier to pass by increasing their moisture content. This type of laxative does not really stimulate bowel movements, but it makes it possible to have bowel movements without straining. Stool softeners are best used to prevent constipation in people who need to avoid straining, because of recent surgery, for example.
  • Three stool-softening agents are available: docusate sodium (COLACE®, REGUTOL®, and others), docusate calcium (SURFAK®, DC SOFTGELS®) and docusate potassium (DIALOSE®, DIOCTO-K®).
  • the 5-HT 4 agonists speed up movement of bowel contents through the colon and reduces sensitivity to intestinal nerve stimulation.
  • Suitable serotonin 5-HT 4 agonists which can be used in combination with the compounds of the invention include sumatriptan, rauwolscine, yohimbine, metoclopramide, prucalopride and tegaserod (ZELNORM®).
  • Spiller R. “Serotonergic Modulating Drugs for Functional Gastrointestinal Diseases,” Br J Clin Pharmacol. 54:11-20 (2002) and U.S. Pat. No. 6,413,988, incorporated herein by reference.
  • Motilin is a peptide of 22 amino acids which is produced in the gastrointestinal system of a number of species. Motilin induces smooth muscle contractions in the stomach tissue of dogs, rabbits, and humans as well as in the colon of rabbits. Apart from local gastrointestinal intestinal tissues, motilin and its receptors have been found in other tissues.
  • motilin Aside from motilin itself, there are other substances which are agonists of the motilin receptor and which elicit gastrointestinal emptying.
  • One of those agents is the antibiotic erythromycin. Studies have shown that erythromycin elicits biological responses that are comparable to motilin itself and therefore can be useful in the treatment of diseases such as chronic idiopathic intestinal pseudo-obstruction and gastroparesis. Weber, F. et al., The American Journal of Gastroenterology, 88:4, 485-90 (1993), incorporated herein by reference.
  • Dopamine antagonists are drugs that bind to, but do not activate, dopamine receptors thereby blocking the actions of dopamine or exogenous agonists.
  • This class of drugs includes, but are not limited to, bethanecol, metoclopramide, domperidone, amisulpride, clebopride, mosapramine, nemonapride, remoxipride, risperidone, sulpiride, sultopride and ziprasidone.
  • cholinesterase inhibitor refers to one or more agents that prolong the action of acetylcholine by inhibiting its destruction or hydrolysis by cholinesterase. Cholinesterase inhibitors are also known as acetylcholinesterase inhibitors.
  • cholinesterase inhibitors include, but are not limited to, edrophonium, neostigmine, neostigmine methylsulfate, pyridostiginie, tacrine and physostigmine, ambenonium chloride (MYTELASE®), edrophonium chloride (TENSILON®), neostigmine (PROSTIGMINE®), piridogstimina (MESTINON®), distigmine bromide, eptastigmine, galanthamine, axeclidine, acetylcholine bromine, acetylcholine chloride, aclatonium napadisilate, benzpyrinium bromide, carbachol, carponium chloride, cemecarium bromide, dexpanthenol, diisopropyl paraoxon, echothiophate chloride, eseridine, furtrethonium, methacholine chloride, muscar
  • Subject refers to animals such as mammals, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, pigs, dogs, cats, rabbits, guinea pigs, rats, mice or other bovine, ovine, equine, canine, feline, rodent or murine species.
  • the mammal is a human.
  • treating and treatment refer to stimulating (e.g., inducing) motility of the gastrointestinal system.
  • therapeutically effective amount refers to an amount sufficient to elicit the desired biological response.
  • the desired biological response is stimulating (e.g., inducing) motility of the gastrointestinal system.
  • the desired biological response is stimulating (e.g., inducing) motility of the gastrointestinal system to treat opioid induced constipation in a subject in need thereof.
  • the subject is using opioids for post-surgical pain management.
  • the subject is using opioids for chronic pain management.
  • the desired biological response is stimulating (e.g., inducing) motility of the gastrointestinal system to treat diabetes related gastroparesis in a subject in need thereof.
  • the desired biological response is stimulating (e.g., inducing) motility of the gastrointestinal system to treat gastroesophageal reflux disease in a subject in need thereof.
  • the gastroesophageal reflux disease is nocturnal gastroesophageal reflux disease.
  • the desired biological response is stimulating (e.g., inducing) motility of the gastrointestinal system to treat irritable bowel syndrome in a subject in need thereof.
  • the irritable bowel syndrome is constipation-predominant irritable bowel syndrome.
  • the irritable bowel syndrome is constipation/diarrhea irritable bowel syndrome.
  • the desired biological response is stimulating (e.g., inducing) motility of the gastrointestinal system to treat constipation in a subject in need thereof.
  • the desired biological response is stimulating (e.g., inducing) motility of the gastrointestinal system to treat post-operative ileus in a subject in need thereof.
  • the therapeutically effective amount or dose will depend on the age, sex and weight of the patient, and the current medical condition of the patient. The skilled artisan will be able to determine appropriate dosages depending on these and other factors to achieve the desired biological response.
  • a suitable dose per day for the growth hormone secretagogue can be in the range of from about 1 ng to about 10,000 mg, about 5 ng to about 9,500 mg, about 10 ng to about 9,000 mg, about 20 ng to about 8,500 mg, about 30 ng to about 7,500 mg, about 40 ng to about 7,000 mg, about 50 ng to about 6,500 mg, about 100 ng to about 6,000 mg, about 200 ng to about 5,500 mg, about 300 ng to about 5,000 mg, about 400 ng to about 4,500 mg, about 500 ng to about 4,000 mg, about 1 ⁇ g to about 3,500 mg, about 5 ⁇ g to about 3,000 mg, about 10 ⁇ g to about 2,600 mg, about 20 ⁇ g to about 2,575 mg, about 30 ⁇ g to about 2,550 mg, about 40 ⁇ g to about 2,500 mg, about 50 ⁇ g to about 2,475 mg, about 100 ⁇ g to about 2,450 mg, about 200 ⁇ g to about 2,425 mg, about 300 ⁇ g to about 2,000, about 400
  • Suitable doses per day for the growth hormone secretagogue include doses of about or greater than 1 ng, about 5 ng, about 10 ng, about 20 ng, about 30 ng, about 40 ng, about 50 ng, about 100 ng, about 200 ng, about 300 ng, about 400 ng, about 500 ng, about 1 ⁇ g, about 5 ⁇ g, about 10 ⁇ g, about 20 ⁇ g, about 30 ⁇ g, about 40 ⁇ g, about 50 ⁇ g, about 100 ⁇ g, about 200 ⁇ g, about 300 ⁇ g, about 400 ⁇ g, about 500 ⁇ g (0.5 mg), about 1 mg, about 1.25 mg, about 1.5 mg, about 2.0 mg, about 2.5 mg, about 3.0 mg, about 3.5 mg, about 4.0 mg, about 4.5 mg, about 5 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 100 mg, about 200 mg, about 300 mg, about 400 mg, about 500 mg, about 600 mg, about 625 mg, about 650 mg
  • a suitable dose of the growth hormone secretagogue can be in the range of from about 0.20 mg to about 4000 mg per day, such as from about 1 mg to about 4000 mg, for example, from about 5 mg to about 3000 mg, such as about 10 mg to about 2400 mg per day.
  • the dose can be administered in a single dosage or in multiple dosages, for example from 1 to 4 or more times per day. When multiple dosages are used, the amount of each dosage can be the same or different.
  • a suitable dose for the additional therapeutic agent can be in same range as described above for the growth hormone secretagogue.
  • the dose of growth hormone secretagogue and additional agent can be the same or different. Suitable doses for the additional agents can be found in the literature.
  • Administration of a growth hormone secretagogue can take place prior to, after or at the same time as treatment with an additional therapeutic agent, such as, for example, a laxative, a H 2 receptor antagonist, a serotonin 5-HT 4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, or a combination thereof.
  • an additional therapeutic agent such as, for example, a laxative, a H 2 receptor antagonist, a serotonin 5-HT 4 agonist, an antacid, an opioid antagonist, a proton pump inhibitor, or a combination thereof.
  • the therapeutic agent can be administered during the period of growth hormone secretagogue administration but does not need to occur over the entire growth hormone secretagogue treatment period.
  • the compounds for use in the method of the invention can be formulated for administration by any suitable route, such as for oral or parenteral, for example, transdermal, transmucosal (e.g., sublingual, lingual, (trans)buccal), vaginal (e.g., trans- and perivaginally), (intra)nasal and (trans)rectal), subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, inhalation, and topical administration.
  • transdermal e.g., sublingual, lingual, (trans)buccal
  • vaginal e.g., trans- and perivaginally
  • intra)nasal and (trans)rectal subcutaneous, intramuscular, intradermal, intra-arterial, intravenous, inhalation, and topical administration.
  • compositions and dosage forms include tablets, capsules, caplets, pills, gel caps, troches, dispersions, suspensions, solutions, syrups, granules, beads, transdermal patches, gels, powders, pellets, magmas, lozenges, creams, pastes, plasters, lotions, discs, suppositories, liquid sprays, dry powders or aerosolized formulations.
  • Suitable oral dosage forms include, for example, tablets, capsules or caplets prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., polyvinylpyrrolidone or hydroxypropylmethylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); disintegrates (e.g., sodium starch glycollate); or wetting agents (e.g., sodium lauryl sulphate).
  • binding agents e.g., polyvinylpyrrolidone or hydroxypropylmethylcellulose
  • fillers e.g., lactose, microcrystalline cellulose or calcium phosphate
  • lubricants e.g., magnesium stearate, talc or silica
  • disintegrates e.g., sodium starch glycollate
  • wetting agents e.g., sodium lauryl sulphate
  • Liquid preparation for oral administration can be in the form of solutions, syrups or suspensions.
  • Liquid preparations e.g., solutions, suspensions and syrups
  • can be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agent (e.g., lecithin or acacia); non-aqueous vehicles (e.g., almond oil, oily esters or ethyl alcohol); and preservatives (e.g., methyl or propyl p-hydroxy benzoates or sorbic acid).
  • suspending agents e.g., sorbitol syrup, methyl cellulose or hydrogenated edible fats
  • emulsifying agent e.g., lecithin or acacia
  • non-aqueous vehicles e.g., almond oil, oily esters or ethyl alcohol
  • preservatives e.g.,
  • pharmaceutically acceptable salt refers to a salt of a compound to be administered prepared from pharmaceutically acceptable non-toxic acids including inorganic acids, organic acids, solvates, hydrates, or clathrates thereof.
  • inorganic acids are hydrochloric, hydrobromic, hydroiodic, nitric, sulfuric, and phosphoric.
  • Appropriate organic acids may be selected, for example, from aliphatic, aromatic, carboxylic and sulfonic classes of organic acids, examples of which are formic, acetic, propionic, succinic, camphorsulfonic, citric, fumaric, gluconic, isethionic, lactic, malic, mucic, tartaric, para-toluenesulfonic, glycolic, glucuronic, maleic, furoic, glutamic, benzoic, anthranilic, salicylic, phenylacetic, mandelic, embonic (pamoic), methanesulfonic, ethanesulfonic, pantothenic, benzenesulfonic (besylate), stearic, sulfanilic, alginic, galacturonic, and the like.
  • the growth hormone secretagogues disclosed can be prepared in the form of their hydrates, such as hemihydrate, monohydrate, dihydrate, trihydrate, tetrahydrate and the like and as solvates.
  • growth hormone secretagogue compounds can be identified, for example, by screening libraries or collections of molecules using suitable methods.
  • Another source for the compounds of interest are combinatorial libraries which can comprise many structurally distinct molecular species.
  • Combinatorial libraries can be used to identify lead compounds or to optimize a previously identified lead.
  • Such libraries can be manufactured by well-known methods of combinatorial chemistry and screened by suitable methods.
  • one of the bonds to the chiral carbon can be depicted as a wedge (bonds to atoms above the plane) and the other can be depicted as a series or wedge of short parallel lines is (bonds to atoms below the plane).
  • the Cahn-Inglod-Prelog system can be used to assign the (R) or (S) configuration to a chiral carbon.
  • a compound of the present invention When a compound of the present invention has two or more chiral carbons, it can have more than two optical isomers and can exist in diastereoisomeric forms. For example, when there are two chiral carbons, the compound can have up to 4 optical isomers and 2 pairs of enantiomers ((S,S)/(R,R) and (R,S)/(S,R)).
  • the pairs of enantiomers e.g., (S,S)/(R,R)
  • the stereoisomers which are not mirror-images e.g., (S,S) and (R,S) are diastereomers.
  • the diastereoisomeric pairs may be separated by methods known to those skilled in the art, for example chromatography or crystallization and the individual enantiomers within each pair may be separated as described above.
  • the present invention includes each diastereoisomer of such compounds and mixtures thereof.
  • the C 1-6 -alkyl, C 1-6 -alkylene, C 1-4 -alkyl or C 1-4 -alkylene groups specified above are intended to include those alkyl or alkylene groups of the designated length in either a linear or branched or cyclic configuration as permitted.
  • Examples of linear alkyl are methyl, ethyl, propyl, butyl, pentyl, and hexyl and their corresponding divalent moieties, such as ethylene.
  • Examples of branched alkyl are isopropyl, sec-butyl, tert-butyl, isopentyl, and isohexyl and their corresponding divalent moieties, such as isopropylene.
  • cyclic alkyl examples include C 3-6 -cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl and their corresponding divalent moieties, such as cyclopropylene.
  • the C 1-6 -alkoxy groups specified above are intended to include those alkoxy groups of the designated length in either a linear or branched or cyclic configuration.
  • linear alkoxy are methoxy, ethoxy, propoxy, butoxy, pentoxy, and hexoxy.
  • branched alkoxy are isopropoxy, sec-butoxy, tert-butoxy, isopentoxy, and isohexoxy.
  • cyclic alkoxy are cyclopropyloxy, cyclobutyloxy, cyclopentyloxy and cyclohexyloxy.
  • the C 1-7 -acyl groups specified above are intended to include those acyl groups of the designated length in either a linear or branched or cyclic configuration.
  • linear acyl are formyl, acetyl, propionyl, butyryl, valeryl, etc.
  • branched are isobutyryl, isovaleryl, pivaloyl, etc.
  • cyclic are cyclopentylcarbonyl, cyclohexylcarbonyl, etc.
  • aryl is intended to include monovalent carbocyclic aromatic ring moieties, being either monocyclic, bicyclic or polycyclic, e.g., phenyl and napthyl, optionally substituted with one or more C 1-6 alkyl, C 1-6 alkoxy, halogen, amino or aryl.
  • arylene is intended to include divalent carbocyclic aromatic ring moieties, being either monocyclic, bicyclic or polycyclic, e.g. selected from the group consisting of phenylene and napthylene, optionally substituted with one or more C 1-6 alkyl, C 1-6 alkoxy, halogen, amino or aryl.
  • heterocyclic aromatic ring moieties being either monocyclic, bicyclic or polycyclic, e.g. selected from the group consisting of pyridyl, 1-H-tetrazol-5-yl, thiazolyl, imidazolyl, indolyl, pyrimidinyl, thiadiazolyl, pyrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thienyl, quinolinyl, pyrazinyl, or isothiazolyl, optionally substituted by one or more C 1-6 alkyl, C 1-6 alkoxy, halogen, amino or aryl.
  • heterocyclic aromatic ring moieties being either monocyclic, bicyclic or polycyclic, e.g. selected from the group consisting of pyridinediyl, 1-H-tetrazolediyl, thiazoldiyl, imidazolediyl, indolediyl, pyrimidinediyl, thiadiazolediyl, pyrazolediyl, oxazolediyl, isoxazolediyl, oxadiazolediyl, thiophenediyl, quinolinediyl, pyrazinediyl, or isothiazolediyl, optionally substituted by one or more C 1-6 alkyl, C 1-6 alkoxy, halogen, amino or aryl.
  • heterocyclic system is intended to include aromatic as well as non-aromatic ring moieties, which may be monocyclic, bicyclic or polycyclic, and contain in their ring structure at least one, such as one, two or three, nitrogen atom(s), and optionally one or more, such as one or two, other hetero atoms, e.g. sulphur or oxygen atoms.
  • the heterocyclic system is preferably selected from pyrazole, pyridazine, triazine, indazole, phthalazine, cinnoline, pyrazolidine, pyrazoline, aziridine, dithiazine, pyrrol, imidazol, pyrazole, isoindole, indole, indazole, purine, pyrrolidine, pyrroline, imidazolidine, imidazoline, pyrazolidine, pyrazoline, piperidine, piperazine, indoline, isoindoline, or morpholine.
  • halogen is intended to include chlorine (Cl), fluorine (F), bromine (Br) and iodine (I).
  • the experiment was conducted to determine the prokinetic effect of the growth hormone secretagogue RC-1139.
  • the compound RC-1139 was tested in normal conscious animals, as well as in the post-operative period, including concomitant morphine administration, to mimic the clinical condition where most post-operative patients are receiving opiate analgesia that can contribute to or increase post-operative gastrointestinal ileus.
  • Gastric emptying was measured by the following technique. Animals were sacrificed by CO 2 inhalation and after 15 min and the abdomen was opened. Stomachs were clamped at the pylorus and cardia were removed and placed in test tubes for counting with the use of a gamma counter the amount of radioactivity left in the stomach. The results are shown in FIG. 1 .
  • RC-1139 were injected intravenously at the end of the methylcellulose administration at time 0.
  • the dose levels of RC-1139 were as follows: 1.0, 2.5 and 10 mg/kg.
  • RC-1139 was given as a 1 min bolus and was well tolerated at all doses.
  • Gastric emptying was measured by the following technique. Animals were sacrificed by CO 2 inhalation after 15 min and the abdomen was opened. Stomachs were clamped at the pylorus and cardia were removed and placed in test tubes for counting with the use of a gamma counter the amount of radioactivity left in the stomach. The results are shown in FIG. 2 .
  • gastric ileus was induced by submitting the rats to laparotomy after anesthesia with isoflurane. The cecum was exteriorized and gently manipulated (patted between hands for 1 minute in saline-soaked gauze). Abdominal muscles were then closed with silk sutures and the animals were allowed to recover for 5 minutes before gavage for gastric emptying studies.
  • a distilled water solution (1.5 ml) containing 1.5% methylcellulose and technitium-99m ( 99m Tc) (approximately 100,000 counts per minute) was then administered intragastrically through stainless steel tube in conscious rats.
  • the substances tested (saline vs. RC-1139) were injected intravenously at the end of the methylcellulose administration at time 0.
  • the dose levels were as follows: 2.5, 10 and 50 mg/kg.
  • RC-1139 was given as a 1 min bolus and was well tolerated at all doses.
  • Gastric emptying was measured by the following technique. Animals were killed by CO 2 inhalation after 15 min and the abdomen was opened. Stomachs were clamped at the pylorus and cardia were removed and placed in test tubes for counting with the use of a gamma counter the amount of radioactivity left in the stomach. The results are shown in FIG. 3 .
  • gastric residue remaining in the stomach was measured 15 min postingestion of the methycellulose solution by counting the amount of 99m Tc in the removed organ. Data expressed in percentage of the administered dose are shown as means ⁇ SEM. Statistical analysis was done by ANOVA (with Tukey-Kramer post-tests with one-to-one comparisons).
  • the gastric residue (99.1 ⁇ 0.5%) could be decreased to 77 ⁇ 4.1 or 71.3 ⁇ 6.7% by RC-1139 at a dose of 2.5 mg/kg or 10 mg/kg respectively (p ⁇ 0.01 for both); these values however were still higher than the normal gastric emptying found in normal basal conditions.
US11/203,639 2004-08-12 2005-08-12 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues Abandoned US20070191283A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
US11/203,639 US20070191283A1 (en) 2004-08-12 2005-08-12 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US12/313,956 US8039456B2 (en) 2004-08-12 2008-11-26 Method of stimulating the motility of the gastrointestinal system using ipamorelin
US12/631,490 US8039457B2 (en) 2004-08-12 2009-12-04 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US13/234,248 US20120010157A1 (en) 2004-08-12 2011-09-16 Method of stimulating the motility of the gastrointestinal system using ipamorelin
US13/234,387 US20120077745A1 (en) 2004-08-12 2011-09-16 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60095904P 2004-08-12 2004-08-12
US11/203,639 US20070191283A1 (en) 2004-08-12 2005-08-12 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/313,956 Continuation-In-Part US8039456B2 (en) 2004-08-12 2008-11-26 Method of stimulating the motility of the gastrointestinal system using ipamorelin
US12/631,490 Continuation US8039457B2 (en) 2004-08-12 2009-12-04 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues

Publications (1)

Publication Number Publication Date
US20070191283A1 true US20070191283A1 (en) 2007-08-16

Family

ID=35908211

Family Applications (3)

Application Number Title Priority Date Filing Date
US11/203,639 Abandoned US20070191283A1 (en) 2004-08-12 2005-08-12 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US12/631,490 Expired - Fee Related US8039457B2 (en) 2004-08-12 2009-12-04 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US13/234,387 Abandoned US20120077745A1 (en) 2004-08-12 2011-09-16 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues

Family Applications After (2)

Application Number Title Priority Date Filing Date
US12/631,490 Expired - Fee Related US8039457B2 (en) 2004-08-12 2009-12-04 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US13/234,387 Abandoned US20120077745A1 (en) 2004-08-12 2011-09-16 Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues

Country Status (17)

Country Link
US (3) US20070191283A1 (ko)
EP (1) EP1789067B8 (ko)
JP (1) JP2008509930A (ko)
KR (2) KR20130048793A (ko)
CN (1) CN101076349B (ko)
AU (1) AU2005272598B2 (ko)
CA (1) CA2576238C (ko)
CY (1) CY1113067T1 (ko)
DK (1) DK1789067T3 (ko)
ES (1) ES2388501T3 (ko)
HK (1) HK1105279A1 (ko)
IL (1) IL181249A (ko)
MX (1) MX2007001477A (ko)
PL (1) PL1789067T3 (ko)
PT (1) PT1789067E (ko)
SI (1) SI1789067T1 (ko)
WO (1) WO2006020930A2 (ko)

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090143310A1 (en) * 2004-08-12 2009-06-04 Sapphire Therapeutics Method of stimulating the motility of the gastrointestinal system using ipamorelin
WO2009082426A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US20100087381A1 (en) * 2004-08-12 2010-04-08 Helsinn Therapeutics (U.S.), Inc. Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues
US7932231B2 (en) * 2005-09-29 2011-04-26 Ipsen Pharma, S.A.S. Compositions and methods for stimulating gastrointestinal motility
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US9821042B2 (en) 2012-02-07 2017-11-21 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US9845287B2 (en) 2012-11-01 2017-12-19 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9957299B2 (en) 2010-08-13 2018-05-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10202431B2 (en) 2007-01-31 2019-02-12 Aileron Therapeutics, Inc. Stabilized P53 peptides and uses thereof
US10213477B2 (en) 2012-02-15 2019-02-26 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10227380B2 (en) 2012-02-15 2019-03-12 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10301351B2 (en) 2007-03-28 2019-05-28 President And Fellows Of Harvard College Stitched polypeptides
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005277389A1 (en) * 2004-08-18 2006-03-02 Elixir Pharmaceuticals, Inc. Growth-hormone secretagogues
US8088733B2 (en) * 2006-07-06 2012-01-03 Tranzyme Pharma Inc. Methods of using macrocyclic agonists of the ghrelin receptor for treatment of gastrointestinal motility disorders
JP2010518090A (ja) 2007-02-09 2010-05-27 トランザイム・ファーマ，インコーポレイテッド 大環状グレリン受容体修飾因子およびその使用方法
TWI429436B (zh) * 2007-04-10 2014-03-11 Helsinn Therapeutics Us Inc 使用生長激素促泌素治療或預防嘔吐之方法
BRPI0911945A2 (pt) * 2008-05-13 2015-10-13 Clarassance Inc cc10 humana recombinante e suas composições para uso no tratamento de rinite nasal
JP5806112B2 (ja) 2008-07-18 2015-11-10 トリニティー セラピューティクス インコーポレイテッド デング出血熱およびデングショック症候群を含む免疫介在性デング熱感染症およびデング熱感染症の抗体依存性増強を処置するための方法
JP5889506B2 (ja) * 2008-09-12 2016-03-22 丸善製薬株式会社 毛乳頭細胞増殖促進剤
UA105657C2 (uk) * 2009-02-27 2014-06-10 Хелсінн Терапьютікс (Ю.Ес.), Інк. Поліпшені способи лікування мігрені на основі анамореліну
CN102812037A (zh) 2009-10-30 2012-12-05 特兰齐姆制药公司 大环生长素释放肽受体拮抗剂和反向激动剂及其使用方法
WO2014105655A1 (en) 2012-12-24 2014-07-03 Neurogastrx, Inc. Methods for treating gi tract disorders
WO2014124209A1 (en) 2013-02-08 2014-08-14 General Mills, Inc. Reduced sodium food products
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
EP3060250A1 (en) 2013-10-22 2016-08-31 NovImmune SA Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of tlr4 ligands and other biomarkers
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
WO2015095391A1 (en) 2013-12-17 2015-06-25 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US9844554B2 (en) 2014-06-24 2017-12-19 Neurogastrx, Inc. Prodrugs of metopimazine
WO2016010771A1 (en) 2014-07-17 2016-01-21 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
TW202246215A (zh) 2015-12-18 2022-12-01 美商亞德利克斯公司 作為非全身ｔｇｒ５促效劑之經取代之４－苯基吡啶化合物
US10836757B1 (en) 2020-04-02 2020-11-17 Neurogastrx, Inc. Polymorphic forms of metopimazine
CN111643501A (zh) * 2020-04-27 2020-09-11 长春金赛药业有限责任公司 Gensci073或其类似物的用途

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767085A (en) * 1993-12-23 1998-06-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5977178A (en) * 1995-12-22 1999-11-02 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127354A (en) * 1996-07-22 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6286927B1 (en) * 1997-12-25 2001-09-11 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6494563B2 (en) * 1997-12-25 2002-12-17 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6548501B2 (en) * 2000-05-31 2003-04-15 Pfizer Inc. Composition and methods for stimulating gastrointestinal motility
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6576648B2 (en) * 1999-11-10 2003-06-10 Novo Nordisk A/S Compound with growth hormone releasing properties
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69322853T2 (de) * 1993-04-30 1999-05-27 St Microelectronics Srl Temperaturstabilisierte Entladestromrückleitungsschaltung zum Treiben einer induktiven Last
US5434171A (en) * 1993-12-08 1995-07-18 Eli Lilly And Company Preparation of 3,4,4-trisubstituted-piperidinyl-N-alkylcarboxylates and intermediates
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
PT1077941E (pt) * 1998-05-11 2010-07-01 Novo Nordisk As Compostos com propriedades de libertaã†o da hormona de crescimento
DK1100824T3 (da) 1998-06-30 2011-06-20 Helsinn Therapeutics Us Inc Forbindelser med væksthormonfrigivende egenskaber
TW592709B (en) 1999-04-29 2004-06-21 Janssen Pharmaceutica Nv Prucalopride oral solution
US6451806B2 (en) * 1999-09-29 2002-09-17 Adolor Corporation Methods and compositions involving opioids and antagonists thereof
US6469030B2 (en) * 1999-11-29 2002-10-22 Adolor Corporation Methods for the treatment and prevention of ileus
AU2001228325A1 (en) * 2000-02-01 2001-08-14 Novo-Nordisk A/S Use of compounds for the regulation of food intake
IL143942A0 (en) 2000-06-29 2002-04-21 Pfizer Prod Inc Use of growth hormone secretagogues for treatment of physical performance decline
US7491695B2 (en) * 2003-06-18 2009-02-17 Tranzyme Pharma Inc. Methods of using macrocyclic modulators of the ghrelin receptor
US20050277677A1 (en) * 2004-06-10 2005-12-15 Heiman Mark L Method for treating emesis with ghrelin agonists
ES2388501T3 (es) * 2004-08-12 2012-10-16 Helsinn Healthcare S.A. Uso de secretagogos de la hormona de crecimiento para estimular la motilidad del sistema gastrointestinal

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5767085A (en) * 1993-12-23 1998-06-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6555570B2 (en) * 1995-12-22 2003-04-29 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5977178A (en) * 1995-12-22 1999-11-02 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6939880B2 (en) * 1995-12-22 2005-09-06 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127391A (en) * 1995-12-22 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6127354A (en) * 1996-07-22 2000-10-03 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6274584B1 (en) * 1996-07-22 2001-08-14 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6286927B1 (en) * 1997-12-25 2001-09-11 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6494563B2 (en) * 1997-12-25 2002-12-17 Canon Kabushiki Kaisha Ink jet element substrate and ink jet head that employs the substrate, and ink jet apparatus on which the head is mounted
US6083908A (en) * 1998-01-16 2000-07-04 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6303620B1 (en) * 1998-05-11 2001-10-16 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6919315B1 (en) * 1998-06-30 2005-07-19 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6566337B1 (en) * 1998-11-03 2003-05-20 Novo Nordisk A/S Compounds with growth hormone releasing properties
US6576648B2 (en) * 1999-11-10 2003-06-10 Novo Nordisk A/S Compound with growth hormone releasing properties
US6548501B2 (en) * 2000-05-31 2003-04-15 Pfizer Inc. Composition and methods for stimulating gastrointestinal motility

Cited By (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100087381A1 (en) * 2004-08-12 2010-04-08 Helsinn Therapeutics (U.S.), Inc. Method of Stimulating the Motility of the Gastrointestinal System Using Growth Hormone Secretagogues
US8039456B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US8039457B2 (en) 2004-08-12 2011-10-18 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
US20090143310A1 (en) * 2004-08-12 2009-06-04 Sapphire Therapeutics Method of stimulating the motility of the gastrointestinal system using ipamorelin
US7932231B2 (en) * 2005-09-29 2011-04-26 Ipsen Pharma, S.A.S. Compositions and methods for stimulating gastrointestinal motility
US10202431B2 (en) 2007-01-31 2019-02-12 Aileron Therapeutics, Inc. Stabilized P53 peptides and uses thereof
US10301351B2 (en) 2007-03-28 2019-05-28 President And Fellows Of Harvard College Stitched polypeptides
WO2009082426A1 (en) * 2007-12-21 2009-07-02 Helsinn Therapeutics (U.S.), Inc. Method of stimulating the motility of the gastrointestinal system using ipamorelin
US9957299B2 (en) 2010-08-13 2018-05-01 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9096684B2 (en) 2011-10-18 2015-08-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US10308699B2 (en) 2011-10-18 2019-06-04 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9522947B2 (en) 2011-10-18 2016-12-20 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9821042B2 (en) 2012-02-07 2017-11-21 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US10039813B2 (en) 2012-02-07 2018-08-07 Massachusetts Institute Of Technology Use of antagonists of ghrelin or ghrelin receptor to prevent or treat stress-sensitive psychiatric illness
US10227380B2 (en) 2012-02-15 2019-03-12 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
US10213477B2 (en) 2012-02-15 2019-02-26 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
US9845287B2 (en) 2012-11-01 2017-12-19 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US10669230B2 (en) 2012-11-01 2020-06-02 Aileron Therapeutics, Inc. Disubstituted amino acids and methods of preparation and use thereof
US9724396B2 (en) 2013-03-15 2017-08-08 Massachusetts Institute Of Technology Use of antagonists of growth hormone or growth hormone receptor to prevent or treat stress-sensitive psychiatric illness
US10471120B2 (en) 2014-09-24 2019-11-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
US10317418B2 (en) 2015-02-24 2019-06-11 Massachusetts Institute Of Technology Use of ghrelin or functional ghrelin receptor agonists to prevent and treat stress-sensitive psychiatric illness
US10253067B2 (en) 2015-03-20 2019-04-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof

Also Published As

Publication number Publication date
CA2576238C (en) 2013-11-12
JP2008509930A (ja) 2008-04-03
CA2576238A1 (en) 2006-02-23
DK1789067T3 (da) 2012-08-27
PL1789067T3 (pl) 2012-10-31
EP1789067B8 (en) 2012-08-15
CY1113067T1 (el) 2016-04-13
CN101076349B (zh) 2012-08-22
SI1789067T1 (sl) 2012-09-28
WO2006020930A3 (en) 2006-11-23
KR20070064593A (ko) 2007-06-21
WO2006020930A2 (en) 2006-02-23
US20100087381A1 (en) 2010-04-08
AU2005272598A1 (en) 2006-02-23
IL181249A0 (en) 2007-07-04
EP1789067A4 (en) 2010-09-01
AU2005272598B2 (en) 2011-11-17
KR20130048793A (ko) 2013-05-10
US8039457B2 (en) 2011-10-18
MX2007001477A (es) 2007-10-10
PT1789067E (pt) 2012-08-06
EP1789067B1 (en) 2012-05-23
US20120077745A1 (en) 2012-03-29
HK1105279A1 (en) 2008-02-06
EP1789067A2 (en) 2007-05-30
IL181249A (en) 2012-02-29
ES2388501T3 (es) 2012-10-16
KR101380200B1 (ko) 2014-04-01
CN101076349A (zh) 2007-11-21

Similar Documents

Publication Publication Date Title
US8039457B2 (en) Method of stimulating the motility of the gastrointestinal system using growth hormone secretagogues
TWI429436B (zh) 使用生長激素促泌素治療或預防嘔吐之方法
US8039456B2 (en) Method of stimulating the motility of the gastrointestinal system using ipamorelin
KR100765579B1 (ko) 제약학적 조합물 및 이의 위장 질병의 치료를 위한 용도
JP2008506651A (ja) Ｄｐｐ−ｉｖ阻害剤と５−ｈｔ３および／または５−ｈｔ４受容体を調節する化合物の組合せ剤
JP2013040206A (ja) 消化器系の運動をイパモレリンを用いて刺激する方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: SAPPHIRE THERAPEUTICS (FORMERLY REJUVENON CORPORAT

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:POLVINO, WILLIAM J.;REEL/FRAME:022429/0982

Effective date: 20060801

AS Assignment

Owner name: HELSINN THERAPEUTICS (U.S.), INC., NEW JERSEY

Free format text: MERGER;ASSIGNOR:SAPPHIRE THERAPEUTICS, INC.;REEL/FRAME:022432/0100

Effective date: 20090128

Owner name: HELSINN THERAPEUTICS (U.S.), INC.,NEW JERSEY

Free format text: MERGER;ASSIGNOR:SAPPHIRE THERAPEUTICS, INC.;REEL/FRAME:022432/0100

Effective date: 20090128

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION